Sorrento’s Partner Mabpharm Files For Infliximab In China
Sorrento Plans US Filing For Infliximab ‘Biobetter’ In 2020
Banking on the burgeoning biosimilars approvals in China, Sorrento’s partner Mabpharm has filed in China for an infliximab biosimilar. Sorrento plans to follow this up with a US filing for a ‘biobetter’ version via the BLA route in 2020.
You may also be interested in...
Celltrion head of clinical development Sang Joon Lee has set out the promise of ‘biobetters’ – biosimilars that improve upon the original reference product – at the FT Global Pharmaceutical and Biotechnology Conference 2019. However, obstacles remain, including the lack of a tailored regulatory pathway.
Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.